Bioscience Americas Achieves Major MilestoneAngie Godinez
Bioscience Americas, LLC, a leading international developer of for-profit adult stem cell therapy centers, announced today that it has achieved a major milestone in its plan to become the first hospital affiliated for-profit provider of adult stem cell treatments for autoimmune diseases in the Western Hemisphere.
The Company intends to bring to market therapies that are FDA approved or that are part of FDA sanctioned clinical trials created by its research partner and licensed from the Global Institute of Stem Cell Therapy and Research.
Working with the Global Institute, Bioscience Americas last year successfully established an affiliation with Hospital in Colombia, South America. The Company recently agreed to business terms with the hospital that should result in significant revenue for Bioscience Americas. is recognized around the world as an acclaimed provider of organ transplants and innovative medical treatments.
In commenting on the Company’s progress CEO Eric Stoffers said that “while there are other stem cell clinics operating in the U.S. and Latin America, the Bioscience Americas clinic represents the first for-profit clinic affiliated with a major hospital. We are first to market positioned to provide autologous, or adult stem cell therapy, to patients throughout the Western Hemisphere.”
serves more than 45,000 patients a year including close to 1,000 organ transplant patients. Mr. Stoffers said that this patient base represents a significant platform from which to launch Bioscience Americas business model. He continued that the Company has developed plans to serve U.S. and other Latin American patients through medical tourism.
“The market we serve is close to $100 billion a year. We intend to capture a significant share of this market. We are well on our way to be in a position to receive our first patient later this year,” Mr. Stoffers concluded.
Bioscience Americas President Bill Deegan added that the Company is raising capital through a Regulation D 506(c) private placement and intends to establish other hospital affiliated autologous stem cell clinics in South America and other Western Hemisphere countries.
Bioscience Americas has licensed more than $450 million in stem cell technology from the Global Institute. In addition, the Company will benefit from more than $50 million in annual research conducted by the Global Institute and its scientific affiliates.
Hospital is a 103-year-old medical institution serving Medellin, Colombia, adjacent communities in the Colombian state of Antioquia, as well as patients from throughout the country. The Bioscience Americas clinic will be housed in ’s new state-of-the-art location in Rio Negro.
The Global Institute of Stem Cell Therapy and Research is a consortium of more than fifteen research scientists from around the world. It is based at the University of California Medical Campus in San Diego and is associated with major research hospitals, medical schools, and research institutions from throughout the world including Harvard University, the Salk Institute for Biological Studies, and the Sanford Burnham Prebys Medical Discovery Institute.